| 5/15/23 |
Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer |
| 5/11/23 |
Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI |
| 5/4/23 |
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results |
| 5/3/23 |
Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference |
| 5/2/23 |
Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention |
| 4/11/23 |
Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference |
| 3/8/23 |
Vir Biotechnology to Participate in the Barclays Global Healthcare Conference |
| 2/28/23 |
Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference |
| 2/23/23 |
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results |
| 2/22/23 |
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE) |
